Novonesis is moving to acquire the remaining stake in Australian biotechnology company MicroBioGen, a deal aimed at strengthening its yeast technology and research capabilities for industrial applications, particularly bioethanol.
Novonesis already owns 23% of MicroBioGen after investing in the company in 2013. The proposed acquisition would bring the two companies’ more than decade-long collaboration under full ownership, expanding Novonesis’ capabilities in advanced yeast solutions.
Ester Baiget, CEO: "This acquisition marks an additional step in our 2030 strategy. It strengthens our yeast capabilities, strengthens our R&D capabilities, and reflects our disciplined investment focus to drive growth."
MicroBioGen brings more than 20 years of yeast genetics expertise and a technology platform focused on improving yeast performance for industrial uses. Its work spans bioethanol, baking, sustainable feed, energy and food applications.
Novonesis said the acquisition will deepen its scientific capabilities in microbiology and industrial fermentation and support the development of new biological solutions for customers.
"We see MicroBioGen as a perfect match building on more than a decade of close collaboration, and we look forward to integrating their technology into Novonesis. With the acquisition, we will continue to strengthen our capabilities and develop the biosolutions our customers need,” said Claus Crone Fuglsang, Chief Scientific Officer, Novonesis.
Novonesis said it will continue supporting MicroBioGen’s existing partners and maintain continuity across its collaborations.
For MicroBioGen, the proposed takeover marks the next step in a relationship that began with Novonesis’ investment more than a decade ago.
Geoffrey Bell, CEO and Co-founder of MicroBioGen, said: "Joining Novonesis is a strong fit for MicroBioGen and its employees. After more than a decade of close collaboration, we could not think of a better home for the company."
The acquisition would give Novonesis full ownership of a key yeast technology partner as it expands its focus on biosolutions and industrial biotechnology.
